User profiles for Parul Thakral
 | parul thakralFortis Memorial Research Institute Verified email at fortishealthcare.com Cited by 282 |
Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE
Objectives The aim of this work was to calculate the radiation absorbed dose to kidneys, liver,
spleen, pituitary gland, and neuroendocrine tumors (NETs) of patients treated with 177 Lu-…
spleen, pituitary gland, and neuroendocrine tumors (NETs) of patients treated with 177 Lu-…
[HTML][HTML] In-house preparation and quality control of Ac-225 prostate-specific membrane antigen-617 for the targeted alpha therapy of castration-resistant prostate …
Purpose: Ac-225 labeled with prostate-specific membrane antigen (PSMA-617), a transmembrane
glycoprotein which is highly expressed in prostate carcinoma cells, is presently being …
glycoprotein which is highly expressed in prostate carcinoma cells, is presently being …
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
…, IB Sen, A Singh, A Sood, R Tauber, P Thakral… - The Lancet …, 2024 - thelancet.com
Background Actinium-225 ( 225 Ac) prostate-specific membrane antigen (PSMA) radioligand
therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC…
therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC…
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using …
Objective: Two radiosensitizing chemotherapeutic drugs, capecitabine (CAP) and temozolomide
(TEM), are administered concurrently to enhance the therapeutic efficacy of peptide …
(TEM), are administered concurrently to enhance the therapeutic efficacy of peptide …
Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver …
P Thakral, I Sen, SS Das, D Manda… - The British Journal of …, 2021 - academic.oup.com
Objective: The aim of the present study was to perform calculation of the absorbed doses to
organs at risk and to neuroendocrine tumors and to determine whether hepatic intra-arterial (…
organs at risk and to neuroendocrine tumors and to determine whether hepatic intra-arterial (…
Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy
I Sen, P Thakral, P Tiwari, V Pant, SS Das… - Annals of Nuclear …, 2021 - Springer
Objectives 225 Ac-PSMA-617 therapy has shown good response in many recent studies. We
report our experience of targeted alpha therapy with 225 Ac-PSMA-617 in mCRPC patients …
report our experience of targeted alpha therapy with 225 Ac-PSMA-617 in mCRPC patients …
[HTML][HTML] An approach for conjugation of 177Lu-DOTA-SCN-Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins …
P Thakral, S Singla, MP Yadav, A Vasisht… - Indian Journal of …, 2014 - journals.lww.com
Methods: Rituximab (BioSim) was desalted with sodium bicarbonate (0.1 M, pH 9.0) and
incubated with DOTA-SCN (1: 50). The effectiveness of the conjugation was evaluated by …
incubated with DOTA-SCN (1: 50). The effectiveness of the conjugation was evaluated by …
Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study
Implementation of radiopharmaceutical therapy dosimetry varies depending on the clinical
application, dosimetry protocol, software, and ultimately the operator. Assessing clinical …
application, dosimetry protocol, software, and ultimately the operator. Assessing clinical …
[HTML][HTML] The Role of PET-CT-Guided Metabolic Biopsies in Improving Yield of Inconclusive Anatomical Biopsies: A Review of 5 Years in a Teaching Hospital
Tumour sampling is indispensable to diagnostic and therapeutic decision making. Thus, 18F-FDG
PET/CT has the potential to accurately discriminate between viable and non-viable …
PET/CT has the potential to accurately discriminate between viable and non-viable …
[HTML][HTML] Rare sites of metastases in prostate cancer detected on Ga-68 PSMA PET/CT scan—a case series
S Dureja, P Thakral, V Pant, I Sen - Indian Journal of Nuclear …, 2017 - journals.lww.com
Ga-68 labeled prostate-specific membrane antigen (PSMA) whole body PET/CT scan is a
novel upcoming modality for the evaluation of prostate cancer. We present three cases of …
novel upcoming modality for the evaluation of prostate cancer. We present three cases of …